brimonidine, topical

(redirected from Mirvaso)

brimonidine, topical

(bri-moe-ni-deen ) ,


(trade name)


Therapeutic: cosmetic agents
Pharmacologic: alpha adrenergic agonists
Pregnancy Category: B


Topical management of persistent (nontransient) facial erythema due to rosacea.


Acts as a seletive alpha-2 adrenergic agonist, causes direct vasoconstriction.

Therapeutic effects

Decreased erythema in rosacea.


Absorption: Some absorption follows topical use.
Distribution: Unk
Metabolism and Excretion: Extensively metabolized by the liver; drug and metabolites are excreted in urine.
Half-life: unk

Time/action profile (decreased erythema)

topwithin 3 hr3–6 hrat least 12 hr


Contraindicated in: Lactation: Discontinue breast feeding or drug
Use Cautiously in: Depression;Cerebral/coronary insufficiency;Reynaud's phenomenon;Severe/unstable/uncontrolled cardiovascular disease;Orthostatic hypotension;Thromboangiitis obliterans;scleroderma;Sjögren's syndrome;Vascular insufficiency (may potentiate) Obstetric: Use only if potential benefit justifies potential fetal risk Pediatric: Safe and effective use in children has not been established; inadvertent ingestion has caused serious adverse effects.

Adverse Reactions/Side Effects

Central nervous system

  • headache

Ear, Eye, Nose, Throat

  • nasopharyngitis


  • flushing (most frequent)
  • contact dermatitis
  • erythema
  • skin burning sensation


Drug-Drug interaction

Due to possible ↓ in blood pressure, use cautiously with antihypertensives, beta-adrenergic blockers, digitalis glycosides May ↑ risk of sedation with alcohol, anti-anxiety agents, barbiturates and opioidssedative/hypnotics.Concurrent use with MAO inhibitors may ↑ risk of systemic side effects, including hypotension, undertake concurrent use with caution.


Topical (Adults >18 yr) Apply pea-sized amount to each of five areas on the face (forehead, chin, nose and each cheek) once daily.


Topical gel: 0.33%

Nursing implications

Nursing assessment

  • Assess face for erythema of rosacea periodically during therapy.

Potential Nursing Diagnoses

Impaired skin integrity (Indications)
Risk for situational low self-esteem (Indications)


  • Topical: Apply a pea-size amount to central forehead, chin, nose, and each cheek. Spread smoothly and evenly as a thin layer across entire face, avoiding eyes and lips. Do not apply to irritated skin or open wounds. Wash hands after application.
    • Not for oral, ophthalmic, or intravaginal use.

Patient/Family Teaching

  • Instruct patient in correct application of brimonidine. Caution patient not to use more gel than prescribed. Advise patient to read Patient Information Leaflet prior to therapy and with each Rx refill in case of changes.
  • Inform patient that erythema or flushing may occur; usually diminishes 30 min to several hrs after application; resolves after discontinuation.
  • Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications.

Evaluation/Desired Outcomes

  • Decreased facial erythema of rosacea.
Drug Guide, © 2015 Farlex and Partners
References in periodicals archive ?
She pointed to a 2017 study that examined a combination treatment of ivermectin 1% topical cream (Soolantra) and brimonidine 0.33% topical gel (Mirvaso) for patients with rosacea with moderate to severe persistent erythema and inflammatory lesions.
M2 PHARMA-August 7, 2017-Perrigo awarded tentative approval from US FDA for generic version of Mirvaso Gel to treat rosacea
M2 EQUITYBITES-August 7, 2017-Perrigo awarded tentative approval from US FDA for generic version of Mirvaso Gel to treat rosacea
Once brimonidine gel (Mirvaso) has quelled the erythema, the inflammatory lesions will stand out even more prominently, noted Dr.
Strategic brands include Epiduo, Oracea, Differin, Mirvaso, Soolantra, TriLuma, Loceryl, Benzac, Cetaphil, Excipial, Daylong, Metvix, Azzalure/ Dysport, Restylane and Emervel.
The sympathomimetic brimonidine at a concentration of 0.33% in a dermatological gel formulation was launched as Mirvaso in April 2014.
A prescription of topical steroids, and sometimes some brimonidine topical gel (Mirvaso) as well can help reduce the redness.
M2 PHARMA-August 24, 2016-Perrigo wins tentative US FDA approval for generic Suprep Oral Solution; Confirms patent challenge for generic Mirvaso Gel
M2 EQUITYBITES-August 24, 2016-Perrigo wins tentative US FDA approval for generic Suprep Oral Solution; Confirms patent challenge for generic Mirvaso Gel
Galderma's strategic brands include Epiduo, Oracea, Clobex, Differin, Mirvaso, Rozex/MetroGel, Silkis/Vectical, Tri-Luma, Loceryl, Metvix, Azzalure, Restylane and Emervel, as well as Cetaphil in the consumer marketplace.
The other addition to the regimen for rosacea is the new 0.33% topical brimonidine gel (Mirvaso), approved by the Food and Drug Administration in August 2013 for the treatment of the facial erythema of rosacea in adults.
Topical preparations containing brimonidine (Mirvaso), azelaic acid, and green tea, as well as oral nicotinamide, can have a temporary effect on reducing skin erythema.